ronopterin

Small moleculeexperimental

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2009 (NCT02012582)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(N)c2N1
Mol. weight
240.27 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2,4-diamino-5,6,7,8-tetrahydro-6(1,2-dihydroxypropyl)pteridine
  • 4-amino-h4biopterin
  • 4-amino-tetrahydrobiopterin
  • ronopterin
  • vas203
  • vas203

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02794168Phase 3Jun 1, 2016ICON, Medical University Innsbruck, Vasopharm GmbH
NCT02992236Phase 1Aug 1, 2015Vasopharm GmbH, Winicker Norimed GmbH
NCT02012582Phase 2Nov 1, 2009Vasopharm GmbH
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Vasopharm GmbHFor profit3332009
ICONFor profit1012016
Medical University InnsbruckAcademic/Hospital1012016
Winicker Norimed GmbHFor profit1012015
4 organizations
Page 1 / 1